Identification and development of mPGES-1 inhibitors: where we are at?

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y, Murakami M. Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie92(6),651–659 (2010).
  Medline CASGoogle Scholar
• 2  Nakanishi M, Montrose DC, Clark P et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res.68(9),3251–3259 (2008).▪▪ First evidence of a role for mPGES-1 knockout in colorectal carcinogenesis.
  Medline CASGoogle Scholar
• 3  Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J. Intern. Med.268(1),5–14 (2010).
  Medline CASGoogle Scholar
• 4  Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev.59(3),207–224 (2007).
  Medline CASGoogle Scholar
• 5  Van Rees BP, Sivula A, Thoren S et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int. J. Cancer107(4),551–556 (2003).
  Medline CASGoogle Scholar
• 6  Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl Acad. Sci. USA96(13),7220–7225 (1999).▪▪ First report published on the identification and characterization of microsomal glutathione-dependent prostaglandin E2 synthase. First suggestion for microsomal prostaglandin E synthase-1 as a novel target for drug development in the area of inflammation and cancer.
  Medline CASGoogle Scholar
• 7  Jegerschold C, Pawelzik SC, Purhonen P et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl Acad. Sci. USA105(32),11110–11115 (2008).
  MedlineGoogle Scholar
• 8  Xing L, Kurumbail RG, Frazier RB et al. Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions. J. Comput. Aided Mol. Des.23(1),13–24 (2009).
  Medline CASGoogle Scholar
• 9  Hetu PO, Ouellet M, Falgueyret JP et al. Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1. Arch. Biochem. Biophys.477(1),155–162 (2008).
  Medline CASGoogle Scholar
• 10  Murakami M, Naraba H, Tanioka T et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem.275(42),32783–32792 (2000).
  Medline CASGoogle Scholar
• 11  Hammarberg T, Hamberg M, Wetterholm A, Hansson H, Samuelsson B, Haeggstrom JZ. Mutation of a critical arginine in microsomal prostaglandin E synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2α. J. Biol. Chem.284(1),301–305 (2009).
  Medline CASGoogle Scholar
• 12  Hamza A, Tong M, Abdulhameed MD et al. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH₂ and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. J. Phys. Chem. B114(16),5605–5616 (2010).
  Medline CASGoogle Scholar
• 13  Watanabe K, Kurihara K, Tokunaga Y, Hayaishi O. Two types of microsomal prostaglandin E synthase: glutathione-dependent and -independent prostaglandin E synthases. Biochem. Biophys. Res. Comm.235(1),148–152 (1997).
  Medline CASGoogle Scholar
• 14  Yamada T, Komoto J, Watanabe K, Ohmiya Y, Takusagawa F. Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2). J. Mol. Biol.348(5),1163–1176 (2005).
  Medline CASGoogle Scholar
• 15  Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem.275(42),32775–32782 (2000).
  Medline CASGoogle Scholar
• 16  Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res.43(1),3–35 (2004).
  Medline CASGoogle Scholar
• 17  Murakami M, Nakashima K, Kamei D et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem.278(39),37937–37947 (2003).
  Medline CASGoogle Scholar
• 18  Jania LA, Chandrasekharan S, Backlund MG et al. Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. Prostaglandins Other Lipid Mediat.88(3–4),73–81 (2009).
  Medline CASGoogle Scholar
• 19  Weaver AJ, Sullivan WP, Felts SJ, Owen BA, Toft DO. Crystal structure and activity of human p23, a heat shock protein 90 co-chaperone. J. Biol. Chem.275(30),23045–23052 (2000).
  Medline CASGoogle Scholar
• 20  Kobayashi T, Nakatani Y, Tanioka T et al. Regulation of cytosolic prostaglandin E synthase by phosphorylation. Biochem. J.381(Pt 1),59–69 (2004).
  Medline CASGoogle Scholar
• 21  Tanikawa N, Ohmiya Y, Ohkubo H et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Comm.291(4),884–889 (2002).
  Medline CASGoogle Scholar
• 22  Nakatani Y, Hokonohara Y, Kakuta S, Sudo K, Iwakura Y, Kudo I. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem. Biophys. Res. Comm.362(2),387–392 (2007).
  Medline CASGoogle Scholar
• 23  Cha YI, Solnica-Krezel L, Dubois RN. Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. Dev. Biol.289(2),263–272 (2006).
  Medline CASGoogle Scholar
• 24  Uematsu S, Matsumoto M, Takeda K, Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J. Immunol.168(11),5811–5816 (2002).
  Medline CASGoogle Scholar
• 25  Trebino CE, Stock JL, Gibbons CP et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl Acad. Sci. USA100(15),9044–9049 (2003).▪▪ Demonstration for a role of mPGES-1 in both acute and chronic PGE2-dependent experimental models of inflammation.
  Medline CASGoogle Scholar
• 26  Thoren S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur. J. Biochem.267(21),6428–6434 (2000).
  Medline CASGoogle Scholar
• 27  Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J. Immunol.167(1),469–474 (2001).
  Medline CASGoogle Scholar
• 28  Mustafa M, Wondimu B, Yucel-Lindberg T, Kats-Hallstrom AT, Jonsson AS, Modeer T. Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts. J. Clin. Periodontol.32(1),6–11 (2005).
  Medline CASGoogle Scholar
• 29  Yucel-Lindberg T, Hallstrom T, Kats A, Mustafa M, Modeer T. Induction of microsomal prostaglandin E synthase-1 in human gingival fibroblasts. Inflammation28(2),89–95 (2004).
  Medline CASGoogle Scholar
• 30  Naraba H, Yokoyama C, Tago N et al. Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J. Biol. Chem.277(32),28601–28608 (2002).
  Medline CASGoogle Scholar
• 31  Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J. Biol. Chem.278(21),19396–19405 (2003).▪▪ Co-expression of COX-2 and mPGES-1 in HEK293 cells leads to tumorigenicity of these cells into mice. First demonstration of a role for mPGES-1 in tumorigenesis.
  Medline CASGoogle Scholar
• 32  Saha S, Engstrom L, Mackerlova L, Jakobsson PJ, Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am. J. Physiol. Regul. Integr. Comp. Physiol.288(5),R1100–R1107 (2005).
  Medline CASGoogle Scholar
• 33  Kamei D, Yamakawa K, Takegoshi Y et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J. Biol. Chem.279(32),33684–33695 (2004).
  Medline CASGoogle Scholar
• 34  Von Rahden BH, Stein HJ, Hartl SA et al. Expression of prostaglandin E synthase in Barrett’s cancer. Dis. Esophagus21(4),304–308 (2008).
  Medline CASGoogle Scholar
• 35  Nardone G, Rocco A, Vaira D et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J. Pathol.202(3),305–312 (2004).
  Medline CASGoogle Scholar
• 36  Jang TJ. Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis. Virchows Arch.445(6),564–571 (2004).
  Medline CASGoogle Scholar
• 37  Gudis K, Tatsuguchi A, Wada K et al. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum. Pathol.38(12),1826–1835 (2007).
  Medline CASGoogle Scholar
• 38  Rocco A, Caruso R, Toracchio S et al. Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression. Ann. Oncol.17(Suppl. 7),103–108 (2006).
  Google Scholar
• 39  Yoshimatsu K, Golijanin D, Paty PB et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res.7(12),3971–3976 (2001).
  Medline CASGoogle Scholar
• 40  Lim SC, Cho H, Lee TB et al. Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med. J.51(5),692–699 (2010).
  MedlineGoogle Scholar
• 41  Takii Y, Abiru S, Fujioka H et al. Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma. Liver Int.27(7),989–996 (2007).
  Medline CASGoogle Scholar
• 42  Nonaka K, Fujioka H, Takii Y et al. mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC. World J. Gastroenterol.16(38),4846–4853 (2010).
  Medline CASGoogle Scholar
• 43  Hasan S, Satake M, Dawson DW et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas37(2),121–127 (2008).
  Medline CASGoogle Scholar
• 44  Mattila S, Tuominen H, Koivukangas J, Stenback F. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Neuropathology29(2),156–165 (2009).
  MedlineGoogle Scholar
• 45  Baryawno N, Sveinbjornsson B, Eksborg S et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro. Oncol.10(5),661–674 (2008).
  Medline CASGoogle Scholar
• 46  Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J. Pathol.208(3),356–363 (2006).
  Medline CASGoogle Scholar
• 47  Gatalica Z, Lilleberg SL, Koul MS et al. COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors. Hum. Pathol.39(10),1495–1504 (2008).
  Medline CASGoogle Scholar
• 48  Omi Y, Shibata N, Okamoto T, Obara T, Kobayashi M. Immunohistochemical demonstration of membrane-bound prostaglandin E2 synthase-1 in papillary thyroid carcinoma. Acta Histochem. Cytochem.42(4),105–109 (2009).
  Medline CASGoogle Scholar
• 49  Kawata R, Hyo S, Araki M, Takenaka H. Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma. Auris. Nasus. Larynx37(4),482–487 (2010).
  MedlineGoogle Scholar
• 50  Cohen EG, Almahmeed T, Du B et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin. Cancer Res.9(9),3425–3430 (2003).
  Medline CASGoogle Scholar
• 51  Golijanin D, Tan JY, Kazior A et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res.10(3),1024–1031 (2004).
  Medline CASGoogle Scholar
• 52  Yoshimatsu K, Altorki NK, Golijanin D et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res.7(9),2669–2674 (2001).
  Medline CASGoogle Scholar
• 53  Wu YC, Su LJ, Wang HW et al. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J. Thorac. Oncol.5(8),1167–1174 (2010).
  MedlineGoogle Scholar
• 54  Wang HW, Hsueh CT, Lin CF et al. Clinical implications of microsomal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer. Ann. Surg. Oncol.13(9),1224–1234 (2006).
  MedlineGoogle Scholar
• 55  Kawata R, Hyo S, Maeda T, Urade Y, Takenaka H. Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx. Acta Otolaryngol.126(6),627–632 (2006).
  Medline CASGoogle Scholar
• 56  Herfs M, Herman L, Hubert P et al. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol. Immunother.58(4),603–614 (2009).
  Medline CASGoogle Scholar
• 57  Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br. J. Cancer85(7),1023–1031 (2001).
  Medline CASGoogle Scholar
• 58  Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol. Cancer5,62 (2006).
  MedlineGoogle Scholar
• 59  Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: a comprehensive invited review “phospholipase A2 and lipid mediators”. Biochimie92(6),660–664 (2010).▪ Concise review of the role of mPGES-1 in colorectal carcinogenesis and the novel inhibitors developed for this target.
  Medline CASGoogle Scholar
• 60  Elander N, Ungerback J, Olsson H, Uematsu S, Akira S, Soderkvist P. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem. Biophys. Res. Comm. (2008).▪ Controvertial report about the effects of mPGES-1 downregulation in intestinal tumorigenesis (in contradiction to [2]).
  MedlineGoogle Scholar
• 61  Hanaka H, Pawelzik SC, Johnsen JI et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc. Natl Acad. Sci. USA106(44),18757–18762 (2009).
  Medline CASGoogle Scholar
• 62  Kamei D, Murakami M, Sasaki Y et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem. J.425(2),361–371 (2010).▪ This report provides evidence that mPGES-1 in both cancer cells and host contributes to tumorigenesis in vitro and in vivo.
  CASGoogle Scholar
• 63  Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, Fitzgerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl Acad. Sci. USA103(39),14507–14512 (2006).▪ Deletion of the mPGES-1 gene in low-density lipoprotein receptor knockout mice retards atherogenesis without affecting blood pressure. The report also confirms the Cheng work by [71].
  Medline CASGoogle Scholar
• 64  Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med.343(21),1520–1528 (2000).
  Medline CASGoogle Scholar
• 65  Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med.352(11),1081–1091 (2005).
  Medline CASGoogle Scholar
• 66  Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation113(25),2906–2913 (2006).
  Medline CASGoogle Scholar
• 67  Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA286(8),954–959 (2001).
  Medline CASGoogle Scholar
• 68  Wu D, Mennerich D, Arndt K et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat.90(1–2),21–25 (2009).
  Medline CASGoogle Scholar
• 69  Wu D, Mennerich D, Arndt K et al. The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot Essent Fatty Acids81(1),31–33 (2009).
  Medline CASGoogle Scholar
• 70  Degousee N, Fazel S, Angoulvant D et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation117(13),1701–1710 (2008).
  Medline CASGoogle Scholar
• 71  Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest.116(5),1391–1399 (2006).▪▪ Reports that mPGES-1 deletion, in contrast to deletion, disruption, or inhibition of or cyclooxygenase 2 (COX-2), does not result in hypertension or a predisposition to thrombosis in normo-lipidemic mice. These important findings suggested that selective mPGES-1 inhibitors would have very low if any cardiotoxic side effects typically associated with COX-2 inhibitors.
  Medline CASGoogle Scholar
• 72  Bannenberg G, Dahlen SE, Luijerink M, Lundqvist G, Morgenstern R. Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers. J. Biol. Chem.274(4),1994–1999 (1999).
  Medline CASGoogle Scholar
• 73  Quraishi O, Mancini JA, Riendeau D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Δ(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol.63(6),1183–1189 (2002).
  Medline CASGoogle Scholar
• 74  Wobst I, Schiffmann S, Birod K et al. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem. Pharmacol.76(1),62–69 (2008).
  Medline CASGoogle Scholar
• 75  Mancini JA, Blood K, Guay J et al. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J. Biol. Chem.276(6),4469–4475 (2001).
  Medline CASGoogle Scholar
• 76  Riendeau D, Aspiotis R, Ethier D et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett.15(14),3352–3355 (2005).
  Medline CASGoogle Scholar
• 77  Sciulli MG, Seta F, Tacconelli S et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br. J. Pharmacol.138(4),634–641 (2003).
  Medline CASGoogle Scholar
• 78  Bage T, Modeer T, Kawakami T, Quezada HC, Yucel-Lindberg T. Regulation of prostaglandin E synthases: effects of siRNA-mediated inhibition of microsomal prostaglandin E synthase-1. Biochim. Biophys. Acta1773(10),1589–1598 (2007).
  Medline CASGoogle Scholar
• 79  Cianchi F, Cortesini C, Magnelli L et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther.5(11),2716–2726 (2006).
  Medline CASGoogle Scholar
• 80  Koeberle A, Siemoneit U, Buhring U et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther.326(3),975–982 (2008).
  Medline CASGoogle Scholar
• 81  Fischer L, Hornig M, Pergola C et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br. J. Pharmacol.152(4),471–480 (2007).
  Medline CASGoogle Scholar
• 82  Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol. Cancer Ther.8(8),2348–2355 (2009).
  Medline CASGoogle Scholar
• 83  Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H, Werz O. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem. Biophys. Res. Comm.388(2),350–354 (2009).
  Medline CASGoogle Scholar
• 84  Koeberle A, Northoff H, Werz O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. Biochem. Pharmacol.77(9),1513–1521 (2009).
  Medline CASGoogle Scholar
• 85  Koeberle A, Pollastro F, Northoff H, Werz O. Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br. J. Pharmacol.156(6),952–961 (2009).
  Medline CASGoogle Scholar
• 86  Bauer J, Koeberle A, Dehm F et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. Biochem. Pharmacol.81(2),259–268 (2011).
  Medline CASGoogle Scholar
• 87  Siemoneit U, Koeberle A, Rossi A et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br. J. Pharmacol.162(1),147–162 (2011).
  Medline CASGoogle Scholar
• 88  Koeberle A, Rossi A, Bauer J et al. Hyperforin, an anti-inflammatory constituent from St. John’s wort, inhibits microsomal prostaglandin E(2) synthase-1 and suppresses prostaglandin E(2) formation in vivo. Front. Pharmacol.2,7 (2011).
  Medline CASGoogle Scholar
• 89  Rao CV. Regulation of COX and LOX by curcumin. Adv. Exp. Med. Biol.595,213–226 (2007).
  MedlineGoogle Scholar
• 90  Charleson S, Prasit P, Leger S et al. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol. Pharmacol.41(5),873–879 (1992).
  Medline CASGoogle Scholar
• 91  Masse F, Guiral S, Fortin LJ et al. An automated multistep high-throughput screening assay for the identification of lead inhibitors of the inducible enzyme mPGES-1. J. Biomol. Screen10(6),599–605 (2005).
  Medline CASGoogle Scholar
• 92  Cote B, Boulet L, Brideau C et al. Substituted phenanthrene imidazoles as potent, selectiveIdentification of a novel, potent and selective inhibitor of mPGES-1 activity, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett.17(24),6816–6820 (2007).
  Medline CASGoogle Scholar
• 93  Pawelzik SC, Uda NR, Spahiu L et al. Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1. J. Biol. Chem.285(38),29254–29261 (2010).
  Medline CASGoogle Scholar
• 94  Xu D, Rowland SE, Clark P et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J. Pharmacol. Exp. Ther.326(3),754–763 (2008).
  Medline CASGoogle Scholar
• 95  Giroux A, Boulet L, Brideau C et al. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett.19(20),5837–5841 (2009).
  Medline CASGoogle Scholar
• 96  Gosselin F, Lau S, Nadeau C, Trinh T, O’shea PD, Davies IW. A practical synthesis of m-prostaglandin E synthase-1 inhibitor MK-7285. J. Org. Chem.74(20),7790–7797 (2009).
  Medline CASGoogle Scholar
• 97  Wu TY, Juteau H, Ducharme Y et al. Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1. Bioorg. Med. Chem. Lett.20(23),6978–6982 (2010).
  Medline CASGoogle Scholar
• 98  Werz O, Greiner C, Koeberle A et al. Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J. Med. Chem.51(17),5449–5453 (2008).
  Medline CASGoogle Scholar
• 99  Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem.51(24),8068–8076 (2008).
  Medline CASGoogle Scholar
• 100  Hieke M, Greiner C, Thieme TM, Schubert-Zsilavecz M, Werz O, Zettl H. A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold. Bioorg. Med. Chem. Lett.21(5),1329–1333 (2011).
  Medline CASGoogle Scholar
• 101  Koeberle A, Rossi A, Zettl H et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Pharmacol. Exp. Ther.332(3),840–848 (2010).
  Medline CASGoogle Scholar
• 102  Hieke M, Greiner C, Dittrich M et al. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E(2) synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid. J. Med. Chem. (2011).
  MedlineGoogle Scholar
• 103  Greiner C, Zettl H, Koeberle A et al. Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1. Bioorg. Med. Chem.19(11),3394–3401 (2011).
  Medline CASGoogle Scholar
• 104  Liedtke AJ, Keck PR, Lehmann F, Koeberle A, Werz O, Laufer SA. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J. Med. Chem.52(15),4968–4972 (2009).
  Medline CASGoogle Scholar
• 105  Karg EM, Luderer S, Pergola C et al. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J. Med. Chem.52(11),3474–3483 (2009).
  Medline CASGoogle Scholar
• 106  Koeberle A, Haberl EM, Rossi A et al. Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1. Bioorg. Med. Chem.17(23),7924–7932 (2009).
  Medline CASGoogle Scholar
• 107  Wang J, Limburg D, Carter J, Mbalaviele G, Gierse J, Vazquez M. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg. Med. Chem. Lett.20(5),1604–1609 (2010).
  Medline CASGoogle Scholar
• 108  Mbalaviele G, Pauley AM, Shaffer AF et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem. Pharmacol.79(10),1445–1454 (2010).▪ This study discusses technical assays to be performed in order to obtain mPGES-1 inhibitors profiles, disctinct from COX-2 inhibitor profiles.
  Medline CASGoogle Scholar
• 109  Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin. Pharmacokinet.26(2),107–120 (1994).
  Medline CASGoogle Scholar
• 110  Chiasson JF, Boulet L, Brideau C et al. Trisubstituted ureas as potent and selective mPGES-1 inhibitors. Bioorg. Med. Chem. Lett.21(5),1488–1492 (2011).
  Medline CASGoogle Scholar
• 111  Bruno A, Di Francesco L, Coletta I et al. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochem. Pharmacol.79(7),974–981 (2010).
  Medline CASGoogle Scholar
• 112  Rorsch F, Wobst I, Zettl H et al. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J. Med. Chem.53(2),911–915 (2010).
  Medline CASGoogle Scholar
• 113  De Simone R, Chini MG, Bruno I et al. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents. J. Med. Chem.54(6),1565–1575 (2011).
  Medline CASGoogle Scholar
• 114  Waltenberger B, Wiechmann K, Bauer J et al. Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E(2) synthase-1 (mPGES-1). J. Med. Chem.54(9),3163–3174 (2011).▪▪ Most recent and compelling study that describes the identification of novel mPGES-1 inhibitor scaffolds from pharmacophore modeling and in silico studies.
  Medline CASGoogle Scholar
• 115  Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol.128(10),525–532 (2002).
  Medline CASGoogle Scholar